Having worked in the pharmaceutical industry, I'll comment that synthetic biochemistry (and now metabolic engineering) have a substantial number of patent vulnerable steps, perhaps comparable to software.

It's kind of neat actually; synthetic chemistry in many ways shares its algorithmic and design-oriented nature with software engineering. Rational drug design will only add to the similarities and overlaps going forward.